Atossa Genetics Stock Analysis
| ATOS Stock | USD 0.64 0.01 1.54% |
IPO Date 8th of November 2012 | 200 Day MA 0.8115 | 50 Day MA 0.715 | Beta 1.099 |
Short and Long Term Debt Total is likely to drop to about 15.4 K in 2026. Net Debt is likely to gain to about (60.8 M) in 2026 Atossa Genetics' financial risk is the risk to Atossa Genetics stockholders that is caused by an increase in debt.
Debt Ratio | First Reported 2010-12-31 | Previous Quarter 0.000485 | Current Value 0.00046 | Quarterly Volatility 0.07916401 |
Atossa Genetics is overvalued with Real Value of 0.59 and Target Price of 5.75. The main objective of Atossa Genetics stock analysis is to determine its intrinsic value, which is an estimate of what Atossa Genetics is worth, separate from its market price. There are two main types of Atossa Genetics' stock analysis: fundamental analysis and technical analysis.
The Atossa Genetics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Atossa Genetics is usually not traded on Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day ( substitute day ), Independence Day. Atossa Stock trading window is adjusted to America/New York timezone.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Atossa Genetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as various price indices. Atossa Stock Analysis Notes
About 19.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.67. Some equities with similar Price to Book (P/B) outperform the market in the long run. Atossa Genetics recorded a loss per share of 0.23. The entity last dividend was issued on the 20th of April 2018. The firm had 1:12 split on the 20th of April 2018. Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington. Atossa Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 6 people. For more info on Atossa Genetics please contact FCAP MD at 206 588 0256 or go to https://www.atossatherapeutics.com.Atossa Genetics Investment Alerts
| Atossa Genetics generated a negative expected return over the last 90 days | |
| Atossa Genetics has some characteristics of a very speculative penny stock | |
| Atossa Genetics has high historical volatility and very poor performance | |
| Net Loss for the year was (25.5 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Atossa Genetics currently holds about 125.54 M in cash with (21.03 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.99, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from finance.yahoo.com: Coya Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug Application for COYA 302 for the Treatment of Frontotemporal Dementia |
Atossa Largest EPS Surprises
Earnings surprises can significantly impact Atossa Genetics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-11-12 | 2025-09-30 | -0.06 | -0.07 | -0.01 | 16 | ||
2025-08-12 | 2025-06-30 | -0.06 | -0.07 | -0.01 | 16 | ||
2024-08-12 | 2024-06-30 | -0.06 | -0.05 | 0.01 | 16 |
Atossa Stock Institutional Investors
| Shares | Goldman Sachs Group Inc | 2025-06-30 | 335 K | Susquehanna International Group, Llp | 2025-06-30 | 273.9 K | Northern Trust Corp | 2025-06-30 | 263.4 K | Connor Clark & Lunn Inv Mgmt Ltd | 2025-06-30 | 198.7 K | Squarepoint Ops Llc | 2025-06-30 | 181.1 K | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 160.9 K | Aster Capital Management (difc) Ltd | 2025-06-30 | 144.9 K | Jain Global Llc | 2025-06-30 | 123.1 K | Bank Of America Corp | 2025-06-30 | 99.6 K | Vanguard Group Inc | 2025-06-30 | 5.8 M | Ameriprise Financial Inc | 2025-06-30 | 3 M |
Atossa Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 82.94 M.Atossa Profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.30) | (0.32) | |
| Return On Capital Employed | (0.35) | (0.37) | |
| Return On Assets | (0.30) | (0.32) | |
| Return On Equity | (0.32) | (0.34) |
Management Efficiency
Atossa Genetics has return on total asset (ROA) of (0.2987) % which means that it has lost $0.2987 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4889) %, meaning that it created substantial loss on money invested by shareholders. Atossa Genetics' management efficiency ratios could be used to measure how well Atossa Genetics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.32 in 2026. Return On Capital Employed is likely to drop to -0.37 in 2026. At this time, Atossa Genetics' Total Assets are comparatively stable compared to the past year. Non Currrent Assets Other is likely to gain to about 2.4 M in 2026, whereas Intangible Assets are likely to drop slightly above 11.4 K in 2026.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.65 | 0.62 | |
| Tangible Book Value Per Share | 0.65 | 0.62 | |
| Enterprise Value Over EBITDA | (1.56) | (1.63) | |
| Price Book Value Ratio | 1.91 | 1.82 | |
| Enterprise Value Multiple | (1.56) | (1.63) | |
| Price Fair Value | 1.91 | 1.82 | |
| Enterprise Value | 54.9 M | 57.6 M |
The management team at Atossa Genetics has a track record of steering the company towards sustained growth. Evaluating their strategies helps in understanding the stock's long-term potential.
Technical Drivers
As of the 26th of January, Atossa Genetics shows the Risk Adjusted Performance of (0.10), mean deviation of 3.04, and Standard Deviation of 4.03. Atossa Genetics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Atossa Genetics variance and potential upside to decide if Atossa Genetics is priced correctly, providing market reflects its regular price of 0.64 per share. As Atossa Genetics is a penny stock we also strongly suggest to validate its jensen alpha numbers.Atossa Genetics Price Movement Analysis
The output start index for this execution was twenty-three with a total number of output elements of thirty-eight. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Atossa Genetics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Atossa Genetics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Atossa Genetics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Atossa Genetics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Atossa Genetics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Atossa Genetics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Atossa Genetics Predictive Daily Indicators
Atossa Genetics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Atossa Genetics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Atossa Genetics Forecast Models
Atossa Genetics' time-series forecasting models are one of many Atossa Genetics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Atossa Genetics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.Atossa Genetics Debt to Cash Allocation
Many companies such as Atossa Genetics, eventually find out that there is only so much market out there to be conquered, and adding the next product or service is only half as profitable per unit as their current endeavors. Eventually, the company will reach a point where cash flows are strong, and extra cash is available but not fully utilized. In this case, the company may start buying back its stock from the public or issue more dividends.
Atossa Genetics currently holds 4.97 M in liabilities. Atossa Genetics has a current ratio of 34.49, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Atossa Genetics' use of debt, we should always consider it together with its cash and equity.Atossa Genetics Total Assets Over Time
Atossa Genetics Assets Financed by Debt
The debt-to-assets ratio shows the degree to which Atossa Genetics uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.Atossa Genetics Debt Ratio | 0.046 |
Atossa Short Long Term Debt Total
Short Long Term Debt Total |
|
About Atossa Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Atossa Genetics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Atossa shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Atossa Genetics. By using and applying Atossa Stock analysis, traders can create a robust methodology for identifying Atossa entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | -8.3 K | -7.9 K | |
| Operating Profit Margin | -8.3 K | -7.9 K | |
| Net Loss | -10.3 K | -9.8 K | |
| Gross Profit Margin | (85.47) | (81.19) |
Current Atossa Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Atossa analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Atossa analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Advice | # of Analysts | |
| 5.75 | Strong Buy | 4 | Odds |
Most Atossa analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Atossa stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Atossa Genetics, talking to its executives and customers, or listening to Atossa conference calls.
Atossa Stock Analysis Indicators
Atossa Genetics stock analysis indicators help investors evaluate how Atossa Genetics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Atossa Genetics shares will generate the highest return on investment. By understating and applying Atossa Genetics stock analysis, traders can identify Atossa Genetics position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 88.6 M | |
| Total Stockholder Equity | 71.5 M | |
| Cash And Short Term Investments | 71.1 M | |
| Net Invested Capital | 71.5 M | |
| Cash | 71.1 M | |
| 200 Day M A | 0.8115 | |
| 50 Day M A | 0.715 | |
| Net Interest Income | 4 M | |
| Total Current Liabilities | 5 M | |
| Investments | -19 K | |
| Stock Based Compensation | 2.3 M | |
| Common Stock Shares Outstanding | 125.9 M | |
| Total Cashflows From Investing Activities | -19 K | |
| Free Cash Flow | -21 M | |
| Operating Income | -27.6 M | |
| Other Current Assets | 3.4 M | |
| Accounts Payable | 679 K | |
| Net Debt | -71.1 M | |
| Depreciation | 17 K | |
| Other Operating Expenses | 27.6 M | |
| Non Current Assets Total | 2 M | |
| Liabilities And Stockholders Equity | 76.4 M | |
| Home Category | Domestic | |
| Non Currrent Assets Other | 2 M |
Additional Tools for Atossa Stock Analysis
When running Atossa Genetics' price analysis, check to measure Atossa Genetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atossa Genetics is operating at the current time. Most of Atossa Genetics' value examination focuses on studying past and present price action to predict the probability of Atossa Genetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Atossa Genetics' price. Additionally, you may evaluate how the addition of Atossa Genetics to your portfolios can decrease your overall portfolio volatility.